| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10285), 1637-1645, 2021 | 387 | 2021 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 223 | 2022 |
| Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial E Abaleke, M Abbas, S Abbasi, A Abbott, A Abdelaziz, S Abdelbadiee, ... The Lancet 397 (10274), 605-612, 2021 | 121 | 2021 |
| Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10289), 2049-2059, 2021 | 111 | 2021 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 399 (10325), 665-676, 2022 | 77 | 2022 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 399 (10320), 143-151, 2022 | 46 | 2022 |
| Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open … O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 401 (10387), 1499-1507, 2023 | 17 | 2023 |
| Opioid prescription at postoperative discharge: a retrospective observational cohort study P Daliya, A Adiamah, F Roslan, E Theophilidou, RD Knaggs, N Levy, ... Anaesthesia 76 (10), 1367-1376, 2021 | 17 | 2021 |
| Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet Diabetes & Endocrinology 11 (12), 905-914, 2023 | 9 | 2023 |
| Clinical and health inequality risk factors for non-COVID-related sepsis during the global COVID-19 pandemic: a national case-control and cohort study X Zhong, D Ashiru-Oredope, A Pate, GP Martin, A Sharma, P Dark, ... EClinicalMedicine 66, 2023 | 3 | 2023 |
| Daughter centrioles assemble preferentially towards the nuclear envelope in Drosophila syncytial embryos NHJ Cunningham, IB Bouhlel, PT Conduit Open biology 12 (1), 210343, 2022 | 3 | 2022 |
| Rapid systematic review on risks and outcomes of sepsis: the influence of risk factors associated with health inequalities S Bladon, D Ashiru-Oredope, N Cunningham, A Pate, GP Martin, X Zhong, ... International Journal for Equity in Health 23 (1), 34, 2024 | 1 | 2024 |
| Lessons identified for a future pandemic N Cunningham, S Hopkins Journal of Antimicrobial Chemotherapy 78 (Supplement_2), ii43-ii49, 2023 | 1 | 2023 |
| Introduction to the ESPAUR webinar and report 2021–2022: key findings and stakeholder engagement N Cunningham, E Casale, C Triggs-Hodge, CS Brown, R Hope, ... Medical Sciences Forum 15 (1), 18, 2023 | 1 | 2023 |
| Reporting England’s progress towards the ambitions in the UK action plan for antimicrobial resistance: the English surveillance programme for antimicrobial utilisation and … D Ashiru-Oredope, N Cunningham, E Casale, B Muller-Pebody, R Hope, ... Journal of Antimicrobial Chemotherapy 78 (10), 2387-2391, 2023 | | 2023 |
